Jaguar Health Completes Pivotal Trial for Canine Diarrhea Drug Crofelemer, Eyes Full FDA Approval
JAGX sits 37% above its 52-week low of $0.313 on light trading volume (0.1× avg).
Summary
Jaguar Health has completed its critical effectiveness trial for crofelemer (Canalevia-CA1), a drug conditionally approved for chemotherapy-induced diarrhea (CID) in dogs. This trial is a mandatory step for the company to obtain full FDA veterinary drug approval, as the current conditional approval is set to expire on December 21, 2026. The company plans to submit the trial results in the second quarter of 2026. This positive product development offers a glimmer of hope amidst the severe financial challenges recently disclosed in Jaguar Health's 10-K and 8-K filings, which included a going concern warning and an ongoing Nasdaq delisting threat. Securing full approval for Canalevia-CA1 is essential for the company to maintain this product on the market and potentially generate much-needed revenue, making it a material de-risking event. Traders should monitor for the release of the trial's topline results and the subsequent FDA submission.
At the time of this announcement, JAGX was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.31 to $15.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.